跳至主要内容
临床试验/NL-OMON52926
NL-OMON52926招募中3 期

Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases in patients with a low clinical risk score - a randomized controlled trial - Adjuvant hepatic arterial infusion pump chemotherapy after resection of CLM

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 230 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
230

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age >= 18 years. • ECOG performance status 0 or 1 • Clinical Risk Score (CRS)
  • of 0-2 • Histologically confirmed colorectal cancer (CRC) • Radiologically
  • confirmed CLM amenable for resection or open ablation • Positioning of a
  • catheter for HAIP chemotherapy is technically feasible based on a CT with early
  • arterial phase with 1mm cuts • Adequate bone marrow, liver and renal function
  • conducted within 15 days prior to inclusion.

排除标准

  • Presence of extrahepatic disease (including positive portal lymph nodes) at
  • the time of liver resection or any time since CRC diagnosis. Patients with
  • small (<= 1 cm) extrahepatic lesions that are not clearly suspicious of
  • metastases are eligible. • Second primary malignancy except in situ carcinoma
  • of the cervix, adequately treated non-melanoma skin cancer, or other malignancy
  • treated at least 5 years previously without evidence of recurrence. • Prior
  • hepatic radiation, resection, or ablation. • CLM requiring two-staged
  • resections. • Liver-first resections. • Postoperative radiation of
  • non-surgically treated (resection or open ablation) CLM • (Partial) portal vein
  • thrombosis.
  • Known DPD-deficiency (heterozygous or homozygous) • Pregnant women or
  • lactating women.
  • History of psychiatric disability judged by the investigator to be clinically
  • significant, precluding informed consent or interfering with compliance for
  • HAIP chemotherapy. • Serious concomitant systemic disorders that would
  • compromise the safety of the patient or his/her ability to complete the study,
  • at the discretion of the investigator. • Organ allografts requiring
  • immunosuppressive therapy.
  • Serious, non-healing wound, ulcer, or bone fracture. • Chronic treatment with
  • corticosteroids (dose of >= 10 mg/day methylprednisolone equivalent excluding
  • inhaled steroids). • Serious infections (uncontrolled or requiring
  • treatment). • Participation in another interventional study for CLM with
  • survival as outcome. • Participation in another prospective study with an
  • interventional medical product. • Any psychological, familial, sociological or
  • geographical condition potentially hampering compliance with the study protocol
  • and follow-up schedule; those conditions should be discussed with the patient
  • before registration in the trial.

研究者

相似试验